SecBot SecBot
Biotech Drug Report Generated Nov 11, 2026

PRX-115

PLX·Protalix BioTherapeutics, Inc.
MIXED
Drug Impact Rating6/10
Trial phase
Phase 2
Time to market
If Phase 2 data in H2 2027 is positive, a Phase 3 program would follow, meaning potential FDA approval/commercialization is likely several years away, likely 2029-2031 at the earliest.
Why 6/10
The next hard, dated catalyst is the Phase 2 RELEASE study topline readout, expected in H2 2027 (approximately 8-13 months from now). This is a mid-stage readout, not a registrational/approval decision, and Protalix has other revenue-generating approved products (Elfabrio, Elelyso), so PRX-115 is a major pipeline driver but not the company's sole value. ImpactScore of 6 reflects a binary Phase 2 readout within ~6-12 months on a significant pipeline asset at a company with other programs.
Actionable Insight MIXED

The next major catalyst is the Phase 2 RELEASE study (NCT07280156) topline results, expected in the second half of 2027. Positive data showing sustained uric acid reduction with infrequent dosing could significantly de-risk the program and support a path to registration. Negative or equivocal results would likely weigh heavily on the stock given PRX-115's importance as the lead pipeline asset. Interim data or updates at medical conferences in the interim could also move the stock.

Price Chart

Loading chart...

Executive Summary

PRX-115 is Protalix BioTherapeutics' (NYSE American: PLX) lead pipeline candidate, a recombinant PEGylated uricase for uncontrolled gout, designed to break down uric acid with less frequent dosing than the only approved competitor, Krystexxa (pegloticase). Phase 1 data presented at ACR 2026 showed a single 36 mg dose kept uric acid below target for up to 12 weeks, with drug levels measurable for up to 85 days. The Phase 2 RELEASE study (NCT07280156) is enrolling, with topline results expected in H2 2027. Protalix is already profitable with growing revenue from approved Fabry (Elfabrio) and Gaucher (Elelyso) products, providing a financial cushion. The stock trades at $2.86 with a mean analyst price target of $11, reflecting optimism about PRX-115's potential, though the long wait for Phase 2 data and competition from established Krystexxa are key risks.

How It Works

PRX-115 is a recombinant PEGylated uricase, an enzyme that breaks down uric acid in the blood. In uncontrolled gout, patients have persistently high uric acid levels that standard oral medications cannot control, leading to painful crystal deposits in joints. PRX-115 is designed to be injected intravenously, where it converts uric acid into a harmless substance called allantoin that the body can easily excrete. The drug is 'PEGylated' (coated with polyethylene glycol) to help it stay in the bloodstream longer and reduce the chance of immune reactions. It is produced using Protalix's proprietary ProCellEx plant cell-based platform.

Trial Status

Phase 1 single ascending dose study completed with data presented at ACR 2024 and ACR 2026. The Phase 2 RELEASE study (NCT07280156) is actively enrolling patients with uncontrolled gout. Topline results are expected in the second half of 2027.

The Two-Sided Case

▲ Bull Case6
Phase 1 data showed that a single 36 mg dose of PRX-115 kept mean plasma uric acid levels below the 6.0 mg/dL therapeutic target for up to 12 weeks, suggesting potential for every-3-months or less frequent dosing versus every-2-weeks for Krystexxa, a major competitive advantage.
PRX-115 plasma levels remained measurable for up to 85 days after a single dose, supporting the potential for infrequent maintenance dosing and improved patient convenience/compliance.
Company management believes PRX-115 has best-in-class potential in uncontrolled gout based on its high specific activity, prolonged half-life, and reduced immunogenicity profile from the ProCellEx platform.
Protalix is already profitable with growing revenue ($75.6M YTD through Q3 2026, up from $43.6M) from approved products Elfabrio and Elelyso, providing non-dilutive funding for PRX-115 development.
Analyst consensus is bullish: 4 Buy/Strong Buy ratings vs 1 Hold, with a mean price target of $11 (approximately 328% upside from the $2.57 prior close). HC Wainwright reiterated Buy in September 2026.
Institutional accumulation was strong in Q2/Q3 2026, with Goldman Sachs (add, +89%), Dimensional Fund Advisors (add, +45-66%), JPMorgan (doubled, +320%), and others adding positions.
▼ Bear Case5
PRX-115 faces entrenched competition from Krystexxa (pegloticase), the only FDA-approved uricase for uncontrolled gout, which was strengthened by FDA approval of methotrexate co-administration in 2022 to reduce infusion reactions and improve response rates.
Phase 2 topline data is not expected until H2 2027, leaving a long period without a binary catalyst. The stock could drift or be subject to macro/sentiment swings in the interim.
Uricase therapies carry inherent safety risks including infusion reactions and immunogenicity. PRX-115's PEGylated design aims to mitigate these, but Phase 2 data will be needed to confirm a differentiated safety profile.
Several institutional holders trimmed or exited positions in Q2/Q3 2026, including Morgan Stanley and UBS, signaling some institutional caution.
The gout treatment landscape is evolving, with novel therapies in development including oral options that could compete with injectable biologics like PRX-115.

Upcoming Catalysts

  • Phase 2 RELEASE study topline results expected H2 2027
  • Potential interim data or updates at medical conferences (e.g., ACR Convergence) in 2027
  • Quarterly earnings reports providing pipeline updates

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Protalix BioTherapeutics, Inc. 8-K PLX ·Originating report

Sources · 8

Hover a chip for the title
1 rttnews.com2 seekingalpha.com3 marketscreener.com4 prnewswire.com5 fox4kc.com6 seekingalpha.com7 streetinsider.com8 ajmc.com